Role of tumor-associated macrophages in renal cell carcinoma pathogenesis
- Authors: Kovaleva O.V.1, Efremov G.D.2, Mikhaylenko D.S.2, Alekseev B.Y.2, Grachev A.N.1
-
Affiliations:
- Blokhin Russian Cancer Research Center
- National Medical Research Radiological Center
- Issue: Vol 13, No 1 (2017)
- Pages: 20-26
- Section: DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. RENAL CANCER
- Published: 30.03.2017
- URL: https://oncourology.abvpress.ru/oncur/article/view/626
- DOI: https://doi.org/10.17650/1726-9776-2017-13-1-20-26
- ID: 626
Cite item
Full Text
Abstract
The role of tumor stroma in malignant tumor pathogenesis cannot be disputed. Macrophages are one of the crucial elements of tumor stroma. Tumor-associated macrophages (TAMs) are type 2-activated macrophages (M2). They were first described in 1992. They carry CD206, CD163, FXIIIa, βIG-H3, stabilin 1, YKL-39, SI-CLP, tenascin С, LOX-1, fibronectin, MARCO, interleukin 1 receptor antagonist (IL-1RA) and other markers. Unlike proinflammatory macrophages (M1), М2 display high anti-inflammatory activity and are responsible for inflammation reaction suppression and tissue recovery in inflamed area. TAMs significantly contribute to tumor progression by stimulating cell proliferation, angiogenesis, and suppression of antitumor immune response. Identification of macrophages in renal tumors involves a limited number of markers, which doesn’t allow making a conclusive answer about their function. However, a correlation between TAMs content and a negative disease prognosis can be considered proven. Studies of M1 and M2 using different markers have shown that renal tumors contain high levels of TAMs with mixed M1/M2 phenotype. TAMs in renal tumors are highly proangiogenic and immunosuppressive. TAMs density can be used as a prognostic marker, but development of an effective treatment strategy aimed at inhibition of TAMs antitumor activity requires systemic research involving a wide panel of M1 and M2 macrophage markers.
About the authors
O. V. Kovaleva
Blokhin Russian Cancer Research Center
24 Kashirskoe Shosse, Moscow 115478
Russian FederationG. D. Efremov
National Medical Research Radiological Center
Author for correspondence.
Email: efremov.gen@yandex.ru
3 2nd Botkinskiy Proezd, Moscow 125284 Russian Federation
D. S. Mikhaylenko
National Medical Research Radiological Center3 2nd Botkinskiy Proezd, Moscow 125284 Russian Federation
B. Ya. Alekseev
National Medical Research Radiological Center3 2nd Botkinskiy Proezd, Moscow 125284 Russian Federation
A. N. Grachev
Blokhin Russian Cancer Research Center
Email: alexei.gratchev@gmail.com
24 Kashirskoe Shosse, Moscow 115478 Russian Federation
References
Supplementary files

